Cancer Res Treat.  2023 Apr;55(2):704-705. 10.4143/crt.2022.1524.

Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib

• Choi JH
• Hur JY
• Won YW

• KMID: 2541257
• DOI: http://doi.org/10.4143/crt.2022.1524

Figure

• 

  Fig. 1 Hepatitis B virus serum markers during course of treatment. ALT, alanine transaminase; AST, aspartate aminotransferase; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B virus surface antibody; HbsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus.

Reference

References

1. Iskender G, Iskender D, Ertek M. Hepatitis B virus reactivation under ibrutinib treatment in a patient with chronic lymphocytic leukemia. Turk J Haematol. 2020; 37:208–9.

2. Innocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, et al. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis: a retrospective multicentric GIMEMA study. Haematologica. 2022; 107:1470–3.

3. Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018; 131:1987–9.

4. Yang S, Zhu R, Li N, Feng Y, Zuo R, Gale RP, et al. Ibrutinib in advanced vhronic lymphocytic leukemia/small lymphocytic lymphoma: lower risk of hepatitis B virus reactivation. Acta Haematol. 2022; 145:54–62.

5. Molica S, Levato L, Mirabelli R, Tedeschi A, Lentini M. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients. Leuk Lymphoma. 2018; 59:2734–6.